CXCL12 and neoplasm: Our studies show that CTCE-9908 is efficacious in inhibiting total tumor burden without significantly reducing primary tumor burden suggesting that targeting CXCL12/CXCR4 axis may be therapeutically beneficial for the management of prostate cancer patients undergoing chemo or radiation therapy.